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Introduction: In this report, we describe challenges we encountered in the clinical management of a patient with
hypoparathyroidism who had previously undergone a bariatric procedure.
Case presentation: We report the case of a 38-year-old Caucasian woman who had undergone a Roux-en-Y gastric
bypass procedure for treatment of obesity. She also had a past history of right lobectomy to treat a benign thyroid
nodule. Another thyroid nodule was diagnosed after her bariatric surgery, so a new thyroid surgery was performed.
Permanent hypoparathyroidism occurred after the second thyroid surgery. A Roux-en-Y gastric bypass resulted
in important weight loss, but the preferential site of calcium absorption was bypassed. The lack of endogenous
parathyroid hormone secretion due to post-surgical hypoparathyroidism abolished the physiological mechanism
that compensates the reduced calcium absorption, which was a challenge for us to overcome. In this report, we
describe our clinical therapeutic choices to maintain normocalcemia and normophosphatemia in this patient.
Higher doses of exogenous calcium citrate, calcitriol and cholecalciferol were used, but hypocalcemia was still
present. To improve vitamin D absorption with resultant improvement of calcium homeostasis, we speculated that
adding pancrelipase to meals would increase lipid absorption and possibly fat-soluble vitamins, including vitamin
D. Only after the addition of pancrelipase did the patient improve without weight regain according to clinical and
laboratory assessments.
Conclusion: The use of exogenous pancreatic enzymes improved calcium homeostasis in this bariatric patient. The
role of these enzymes on vitamin D absorption and subsequent rise in calcium levels in hypoparathyroid patients
who undergo bariatric procedures need further investigation.
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Obesity affects over 300 million individuals worldwide,
and many of them are surgically treated. Roux-en-Y gastric
bypass (RYGB) is a bariatric procedure aimed at weight re-
duction in morbidly obese patients. It bypasses the prefer-
ential sites for calcium and vitamin D absorption, placing
patients at risk for altered calcium homeostasis. To com-
pensate the secondary hypocalcemia, bariatric patients are
prone to augment parathyroid hormone (PTH) levels.* Correspondence: gkraemer@ig.com.br
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unless otherwise stated.Thyroid nodules are detected by ultrasound in 19% to
67% of randomly selected individuals. Once detected,
thyroid cancer should be excluded. A relationship be-
tween excessive adiposity and thyroid cancer risk has
been established [1,2], which puts obese as well as
bariatric patients at risk for undergoing thyroidectomy.
Primary hypoparathyroidism, one of the most serious
complications following thyroid surgery, is characterized
by hypocalcemia and hyperphosphatemia with absent or
inappropriately low levels of PTH. Intestinal absorption
of calcium and vitamin D is fundamental in the clinical
management of hypoparathyroidism.ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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underwent total thyroidectomy for a thyroid nodule that
was complicated with permanent hypoparathyroidism.
Our goal is to emphasize the difficulties in the clinical
management of hypoparathyroidism in a bariatric pa-
tient and to relate our therapeutic choices to achieve
normocalcemia.
Case presentation
A 38-year-old Caucasian woman was diagnosed with a left-
sided neck nodule six months after undergoing RYGB to
treat obesity. She recalled palpating a vague mass on the
cervical site before her RYGB, but this mass became more
pronounced only after she lost 33kg. (Her body mass index
(BMI) had changed from 43.5kg/m2 to 30.5kg/m2). She re-
ported a past history (prior to her RYGB) of a right lobec-
tomy of the thyroid to treat a benign nodule, as well as
hypertension and obstructive sleep apnea. Before undergo-
ing the second thyroid surgery and during her first visit at
our clinic, she brought laboratory results showing normal
levels of calcium, phosphorus, 25-hydroxyvitamin D (25
(OH)D), PTH and thyroid-stimulating hormone (TSH).
To investigate the cervical mass, a thyroid ultrasound
was performed. The scan showed a 3.1×2.2×2.0cm hypoe-
choic nodule on the left lobe. Subsequently an aspirative
biopsy was obtained. Cytopathology suggested a Hurthle
cell lesion. Total thyroidectomy was indicated and hence
carried out, and the diagnosis of Hurthle cell adenoma
was confirmed. Immediately after surgery, the patient
had hypocalcemia and required an intravenous calcium
gluconate infusion to stabilize her calcemia. All of the la-
boratory data obtained during clinical management are
provided in Table 1.
Two months after her total thyroidectomy, she was re-
ferred to our unit’s care center by the surgeons because of
difficulties in the clinical management of hypoparathyroid-
ism. Meanwhile, she was admitted several times to an
emergency room to reverse hypocalcemia with intraven-
ous calcium infusions. During her visit at our unit, she re-
ported paresthesias, muscle cramps and tingling in the
mouth. A physical examination revealed that she had posi-
tive Chvostek’s and Trousseau’s signs. Her serum calcium
and phosphorus levels were 5.9mg/dl and 7.1mg/dl, re-
spectively. Her TSH level was 16.6μUI/ml. She was being
treated with levothyroxine 100μg/day, calcium carbonate
7.5g/day, oral calcitriol 2.0μg twice daily and a multivita-
min tablet. Doses of levothyroxine and calcium carbonate
were increased to 150μg/day and 12g/day, respectively,
and magnesium oxide 400mg tablet three times per day
was added. Strict instructions about sunlight exposure
(20min/day) and diet were given. All these measures
improved her calcium homeostasis and avoided any fur-
ther hospitalization. At her three-month follow-up exam-
ination, it was discovered that her calcium level hadincreased and her phosphorus level had decreased (see
Table 1). She had a low PTH level and a normal TSH level.
Her magnesium and albumin levels and renal and hepatic
function were within normal ranges (NRs). We decided to
change calcium carbonate to citrate (12g/day) and to add
cholecalciferol (12,000IU/day).
One month later, her symptoms were partially im-
proved, and she reported that our advice about sunlight
exposure was not being completely followed. Minimal
changes in laboratory data were noticed, and her urinary
calcium/creatinine ratio was 0.09 (NR<0.20). Because of
the large amount of tablets/pills needed for daily intake at
that time, we speculated that she could be a candidate for
surgical reversal of the bariatric procedure; however, she
definitively rejected it, fearing weight regain. Facing this
challenge, and without financial resources to cope with
synthetic PTH hormone treatment, we hypothesized that
the use of pancrelipase could improve fat absorption at
the alimentary tract with possible positive effects on vita-
min D absorption and subsequently on calcium homeosta-
sis. To test our hypothesis, pancrelipase was added at
mealtime (three times per day) (compound capsule con-
taining 10,000 USP units of lipase, 37,500 USP units of
protease and 33,200 USP units of amylase). After continu-
ous use of pancrelipase without side effects, her symptoms
gradually improved until she became totally asymptom-
atic. Two months later, she had serum calcium and phos-
phorus levels of 7.2mg/dl and 5.0mg/dl, respectively. We
increased her calcium citrate dosage to 14g/day. After two
months, her levels of calcium, phosphorus and 25(OH)D
were 7.8mg/dl, 5.2mg/dl and 67.9μg/L, respectively. At
that time, her calciuria was 62.6mg/24h (NR, 50mg/24h to
250mg/24h), and her phosphaturia was 405mg/24h (NR,
340mg/24h to 1300mg/24h). Calcitriol was subsequently
reduced to 1.5μg three times daily.
Her symptoms had completely remitted at 10 months
after thyroidectomy. Her levels of calcium were within,
and eventually slightly below, the NR. She became preg-
nant, and, during the second trimester, although asymp-
tomatic, she had hypocalcemia with normal levels of
phosphorus and 25(OH)D (Table 1, 14 months). Cal-
cium citrate was increased to 18g/day, which stabilized
calcium homeostasis from the sixth month of pregnancy
until delivery. She gave birth to a healthy newborn at
term and breastfed her baby during the first six months.
At present, her symptoms have remitted and her cal-
cium, phosphorus and 25(OH)D levels are within NR.
However, she still ingests an excessive daily number of
tablets and/or pills (a total of 45/day). She has not
regained weight (65kg; BMI, 25.7kg/m2).
Discussion
After bariatric surgery, and independently of multivita-
min and/or mineral supplementation, the incidence of









Drugs used to manage calcium metabolism
(dose/day)
Normal ranges 8.4 to 10.2 3.5 to 5.0 30 to 80 10 to 65
After RYGB and before TT 9.0 4.2 64.4 27.9
2 months post-TT 5.9b 7.1 – – Calcium carbonate (7.5g)
Calcitriol (2μg)
3 months post-TT 6.2b 6.8 76.6 7.1 Calcium carbonate
Calcitriol (2μg)
4 months post-TT 6.8b 6.8 16.4 – Calcium citrate (12g)
Cholecalciferol (12,000IU)
Calcitriol (2μg)
















a25(OH)D, 25-hydroxyvitamin D; PTH, Parathyroid hormone; RYGB, Roux-en-Y gastric bypass; TT, Total thyroidectomy. bTotal calcium was corrected by
albumin levels.
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deficiency ranges from 50% to 63% [3]. The duodenum
and jejunum are the preferential sites for calcium ab-
sorption, and, after a RYGB, they are bypassed. The duo-
denum can absorb 80% to 100% of calcium by vitamin
D–dependent, transcellular active transport, but, when it
is bypassed, the calcium absorption takes place through
a less efficient paracellular mechanism [4]. It is known
that malabsorption of fat-soluble vitamins caused by
poor mixing of bile salts decreases the amount of vita-
min D available and contributes further to deficient
calcium homeostasis [3]. Additionally, partial gastrec-
tomy reduces gastric acidity, resulting in an impaired ab-
sorption of calcium salts. Complicating this scenario is
that these patients usually follow a low-calcium diet
because of low tolerance of calcium-rich dairy products
[4]. Therefore, to stabilize calcium levels, secondary
hyperparathyroidism may occur. However, in the presentcase, the absence of functional parathyroids precluded the
physiological compensatory mechanism. Therefore, we
focused treatment on improvement of the intestinal absorp-
tion of calcium. Considering that it is well established that
cutaneous synthesis of vitamin D is responsible for up to
90% of its source, we first recommended increased calcium
dietary intake and sunlight exposure. Calcium carbonate
was changed to calcium citrate to improve calcium absorp-
tion, which was impaired by achloridia after RYGB [4]. Pan-
creatic exocrine insufficiency is a possible complication of
partial or total gastrectomy [5,6]. Originally, in an attempt
to improve intestinal calcium absorption, we added pan-
crelipase to meals, based on speculation that lipids, and
consequently fat-soluble vitamins (specifically vitamin
D), could have an improved absorption with possible
beneficial effects on calcium homeostasis. The indication
for substitutive therapy with pancreatic enzymes in
asymptomatic patients is debatable. However, a study has
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and consistently low levels of vitamins (such as liposoluble
vitamins) can revert to normal status with pancreatic en-
zyme substitution therapy [7]. Fortunately, associated with
other measures that we employed, this therapeutic choice
produced successful results based on clinical and labora-
tory test results.
Other therapeutic measures, such as thiazides, to en-
hance distal renal tubular calcium reabsorption are used as
adjunctive therapy for hypoparathyroidism [8]. In the
present case, however, because of low systolic blood pres-
sure (90mmHg) and calciuria, we did not recommend such
therapy. Daily costs of synthetic PTH therapy prevented an
indication for this therapy, although it is known that in
hypoparathyroidism it is able to reduce daily requirements
of calcium and vitamin D, of calciuria and of ectopic soft-
tissue calcification, while improving bone health [9].
Magnesium has a critical role as an activator of many
ionic carriers, which is essential not solely for neuro-
muscular excitability but also for transcription of the
PTH gene and for binding of PTH to type 1 receptors
in the bones and kidneys [10]. As we did not know
whether the patient would have an intact parathyroid,
we prescribed magnesium supplementation primarily to
improve neuromuscular hyperexcitability symptoms.
Despite the fact that magnesium deficiency is relatively
rare in a bariatric patient, it can occur after RYGB with
severe and refractory symptomatic hypocalcemia.
A few studies in which clinicians followed bariatric pa-
tients with hypoparathyroidism have demonstrated the
usefulness of concomitant replacement of calcitriol and
cholecalciferol in improving calcium levels [11,12]. Cal-
citriol may improve hypocalcemic symptoms faster be-
cause it has a biological half-life of four to six hours,
whereas cholecalciferol requires hydroxylation in the
liver and kidneys to become active and may take two to
three weeks to produce its effects.
Clinical and laboratory improvement was observed be-
fore our patient’s pregnancy. However, there is some evi-
dence that this condition is related to stabilization of
calcium levels because the placenta is an external source
of calcitriol [13]. Additionally, lactation is associated
with increased serum levels of PTH-related protein and
alkaline phosphatase, which results in a rise in calcemia
[14]. These two physiological conditions might have
aided our patient’s calcium homeostasis during preg-
nancy and lactation.
Although recently our patient’s hypoparathyroidism has
been well compensated, her quality of life is somewhat
impaired by the high number of tablets and pills that must
be ingested, and she is still at risk for hypocalcemia.
Reversal of RYGB due to refractory hypoparathyroidism
remains a possible option for this patient in long-term
follow-up [15].Conclusions
This case illustrates the challenge for the clinical man-
agement of hypoparathyroidism in a bariatric patient.
The value of exogenous pancreatic enzymes on calcium
and vitamin D absorption remains speculative and needs
further investigation.
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